Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Giuliano, Furlini"'
Autor:
Elisabetta Loggi, Silvia Galli, Giovanni Vitale, Roberto Di Donato, Ranka Vukotic, Elena Grandini, Marzia Margotti, Valeria Guarneri, Giuliano Furlini, Claudio Galli, Maria Carla Re, Pietro Andreone
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0187755 (2017)
To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs).Ninety-six patients treated wi
Externí odkaz:
https://doaj.org/article/bdde1149222f4ab28ab2385269a65868
Autor:
Fabio Conti, Ranka Vukotic, Stefania Lorenzini, Anna Riili, Carmela Cursaro, Alessandra Scuteri, Elisabetta Loggi, Silvia Galli, Giuliano Furlini, Mauro Bernardi, Pietro Andreone, MD.
Publikováno v:
Annals of Hepatology, Vol 13, Iss 2, Pp 196-203 (2014)
Background and aim. In patients with chronic hepatitis C receiving Peg interferon/ribavirin (PEG-IFN/RBV) who do not achieve ≥ 2log-reduction in HCV-RNA at week 12 (null responders, NR) and in those with ≥ 2log-decrease but detectable at week 24
Externí odkaz:
https://doaj.org/article/45fe2b76ec234ea88b126e010465c585
Autor:
Barbara, Rossetti, Elisabetta, Loggi, Spertilli Raffaelli, Chiara, Simona, Mercinelli, Claudia Gandolfo, Gianni Gori Savellini, Silvia, Galli, Giovanni, Vitale, Roberto Di Donato, Ranka, Vukotic, Elena, Grandini, Marzia, Margotti, Valeria, Guarneri, Giuliano, Furlini, Maria Carla Re, Andrea De Luca, Pietro, Andreone, Claudio, Galli, MARIA GRAZIA CUSI
Publikováno v:
Università degli Studi di Siena-IRIS
Scopus-Elsevier
Scopus-Elsevier
Hepatitis C virus (HCV) Core Antigen (HCVAg) and HCV-RNA were tested in 962 plasma/serum samples from 180 patients during Direct Antiviral Agents (DAAs) treatment and at follow-up. One hundred and eighty individuals were included: 71% carried advance
Autor:
Elisabetta Loggi, Florian K Bihl, Carmela Cursaro, Camilla Granieri, Silvia Galli, Lucia Brodosi, Giuliano Furlini, Mauro Bernardi, Christian Brander, Pietro Andreone
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e65327 (2013)
BACKGROUND AIMS: The immune impairment characterizing chronic hepatitis B (cHBV) infection is thought to be the consequence of persistent exposure to viral antigens. However, the immune correlates of different clinical stages of cHBV and their relati
Externí odkaz:
https://doaj.org/article/128e58ff178a49d8bec7e1a6ef127c9f
Autor:
Mario Minichiello, A. Scuteri, Elisabetta Loggi, Fabio Conti, E. Grandini, Giovanni Vitale, Giuliano Furlini, Roberto Di Donato, Silvia Galli, Pietro Andreone, Carmela Cursaro, Stefano Gitto
Publikováno v:
Journal of Clinical Virology. 93:66-70
Background Hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients treated with IFN-free direct acting antiviral (DAA) therapies has recently emerged as a potential risk. Given the potential burden of this issue, further data are needed
Autor:
Annagiulia Gramenzi, L. Micco, Silvia Galli, Pietro Andreone, Elisabetta Loggi, Mauro Bernardi, Sirio Fiorino, Stefano Gitto, Claudio Galli, Carmela Cursaro, Giuliano Furlini
Publikováno v:
Journal of Viral Hepatitis. 18:e468-e474
Serum hepatitis B virus surface antigen (HBsAg) levels have been suggested to predict interferon response in chronic hepatitis B. A few data are available on the role of HBsAg measurement in nucleos(t)ide analogues (NA) treatment. We retrospectively
Autor:
Isabella Quinti, Gustavo Cilla, Luciano Balbo, Maria Grazia Meliconi, A Alfarano, Anders Sönnerborg, Giuliano Furlini, Harry van Drimmelen, Paolo Laccetti, Silvia Galli, Sheila Burns, Marie-Louise Newell, Lucy Pembrey, Susanne Polywka, Nick Hallam, Giancarlo Icardi, Esther Serrano, Giuseppe Portella, Bianca Bruzzone, Pier-Angelo Tovo
Publikováno v:
Journal of Medical Virology. 69:195-201
To investigate whether it is appropriate to assume comparability of hepatitis virus C (HCV)-RNA results across laboratories in multi-centre studies, nine laboratories of the European Paediatric HCV Network participated in an international proficiency
Autor:
Giuliano Furlini, Davide Gibellini, Paola Monari, Maria Carla Re, Francesca Vitone, M. La Placa, Pasqua Schiavone, Isabella Bon, Marco Borderi
Publikováno v:
International Journal of Antimicrobial Agents. 20:223-226
The study evaluated the development of drug resistance in a group of HIV-1 patients. After failure to respond to previous therapy with two non-nucleoside reverse transcriptase inhibitors (NNRTIs), as assessed by the presence of a rebound in viral loa
Autor:
M. La Placa, Davide Gibellini, M. Vignoli, Giuliano Furlini, Francesca Vitone, Vincenzo Colangeli, Maria Carla Re
Publikováno v:
Journal of Clinical Virology. 21:81-89
Background: The efficacy of a specific humoral response to transactivating Tat protein was studied in a group of HIV-1 seropositive drug addicts, who had previously received a similar course of anti-retroviral treatment with two reverse transcriptase
Publikováno v:
Journal of Hematotherapy & Stem Cell Research. 9:39-45
Two CD34+ human hematopoietic progenitor cell (HPC) lines, KG-1 and TF-1, became susceptible to human immunodeficiency virus type 1 (HIV-1) infection in the presence of a concurrent infection by human herpesvirus-6 (HHV-6). We have analyzed the possi